Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RENAISSANCE Study: SPN-817 in Adult Patients With Treatment Resistant Epilepsy
NCT05518578Phase 2Recruiting
- Sponsor
- Supernus Pharmaceuticals, Inc.
- Start
- Feb 2023
- Primary completion
- Dec 2027
- Modality
- Nucleic Acid-Directed Small Molecules, Covalent Small Molecules, Classical Binding Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of Huperzine A in epilepsy, sponsored by Supernus Pharmaceuticals, Inc. Primary endpoint: Safety and Tolerability at 72 weeks. Started Feb 2023; status: recruiting.
02
Drugs
Huperzine A
03
Conditions
epilepsy
Beyond the preview
Go deeper on NCT05518578.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05518578.